Large cell neuroendocrine lung carcinoma
Clinical trials for Large cell neuroendocrine lung carcinoma explained in plain language.
Never miss a new study
Get alerted when new Large cell neuroendocrine lung carcinoma trials appear
Sign up with your email to follow new studies for Large cell neuroendocrine lung carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial
Disease control OngoingThis early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …
Matched conditions: LARGE CELL NEUROENDOCRINE LUNG CARCINOMA
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental combo aims to boost immune attack on tough lung cancers
Disease control OngoingThis early-stage trial tests two drugs, obrixtamig and ezabenlimab, given together as infusions to adults with advanced small cell lung cancer or other neuroendocrine tumors that have a specific marker called DLL3. The main goal is to find the highest safe dose of obrixtamig when…
Matched conditions: LARGE CELL NEUROENDOCRINE LUNG CARCINOMA
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC